

Dear Editor,

We have enclosed the revised version of our manuscript entitled “TRANSIENT ELASTOGRAPHY (FIBROSCAN®) WITH CONTROLLED ATTENUATION PARAMETER (CAP) IN THE ASSESSMENT OF LIVER STEATOSIS AND FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE – WHERE DO WE STAND?”

We thank you and the reviewers for the very helpful comments. We accepted all the comments and have included our responses below. We hope the revised version is acceptable for publication.

REVIEWER EVALUATION

Comments to the Author:

Reviewer 1:

Comment 1. In this review, the authors present a deep analysis of the topic, going thoroughly through the most important data, facts and clinically relevant information, which are supported by a vast number of references, even own publications on this topic. The authors also present, in a straightforward way, the actual problems of TE and the role that TE could play in the diagnostics of NAFLD. Furthermore, such a summary has not been available in the literature yet.

Response 1. Thank You

Reviewer 2:

Comment 1. The article is suitable for publication

Response 1. Thank You

Reviewer 3:

Comment 1. The authors have done a commendable job in reviewing the details on Fibroscan from its basics to its applied uses. However, I would like to point out certain things 1. The pathogenesis need not be explained in great detail in the review

Response 1. Thank You, we have corrected.

Comment 2. A comparative data and studies with ARFI and MRI would be worthwhile rather than stating just in a sentence that MRI has fared better and there are cost issues. But enlisting the data about it should be worthwhile.

Response 2. Thank You, we have done it.

Comment 3. ARFI and Te are compared in lot of studies and people have preferred ARFI, authors should give their take on the belief.

Resposne 3. Thank You, we have done it.

Comment 4. The name of the authors in the tables should be corrected for mistakes.

Resposne 4. Thank You, we have corrected.

With best regards, Ivana Mikolasevic